Dianthus Therapeutics (87E) Stock Overview
A clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
87E Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Dianthus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$77.00 |
| 52 Week High | US$81.00 |
| 52 Week Low | US$14.50 |
| Beta | 0.089 |
| 1 Month Change | 0% |
| 3 Month Change | 82.46% |
| 1 Year Change | 381.25% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 558.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 87E | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.7% | 0.9% | 3.2% |
| 1Y | 381.3% | -12.2% | 2.5% |
Return vs Industry: 87E exceeded the German Biotechs industry which returned -11.9% over the past year.
Return vs Market: 87E exceeded the German Market which returned 0.2% over the past year.
Price Volatility
| 87E volatility | |
|---|---|
| 87E Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.6% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 87E's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 87E's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 92 | Marino Garcia | dianthustx.com |
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc. Fundamentals Summary
| 87E fundamental statistics | |
|---|---|
| Market cap | €4.22b |
| Earnings (TTM) | -€149.63m |
| Revenue (TTM) | €1.15m |
Is 87E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 87E income statement (TTM) | |
|---|---|
| Revenue | US$1.34m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.34m |
| Other Expenses | US$175.00m |
| Earnings | -US$173.66m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | -12,998.50% |
| Debt/Equity Ratio | 0% |
How did 87E perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 12:49 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dianthus Therapeutics, Inc. is covered by 18 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Colleen Kusy | Baird |
| null null | Baird |